| Specification | Content | Appearance |
| Troche | 3.6mg/piece |  |
| 5.4mg/piece |  |
|
| 16mg/piece |  |
[Properties] This product is a white to white sac-like coated tablet with AQ and half chip markings on both sides and S, M or L corresponding to different tablet specifications.
Olatinib is a synthetic intracellular non-receptor tyrosine kinase (JAK) inhibitor that acts by inhibiting a variety of pruritus, inflammatory cytokines and allergen-related cytokines that depend on the activity of JAK1 and JAK3 enzymes. The drug had no effect on the cytokines involved in hematopoiesis (which depend on JAK2). Dogs absorbed the drug quickly and well after oral administration. The dietary status of dogs had no significant effect on absorption rate or degree. The elimination half-life of intravenous and oral administration is similar, the absolute bioavailability of the drug is 89%, and the binding rate to plasma protein is low (66.3% to 69.7%). Drugs are metabolized into a variety of metabolites in dogs, with one major oxidative metabolite detectable in plasma and urine. It is mainly metabolically cleared, but also partially excreted through the kidneys and bile. This drug is not classified as a corticosteroid or antihistamine. It has not been evaluated in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressants.
